| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 13 Nov 2026 | SCHEDULE 13G |
| 10 Nov 2026 | SCHEDULE 13D/A |
| 10 Nov 2026 |
Form 4: Daewoong Co., Ltd, 10% owner
Received 11,236,631 shares by exercise ($1.12K) · Disposed of 3,822 shares (Other Transaction) ($1.12K) |
| 03 Nov 2026 | 424B3 |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT TO TWO-YEAR MILESTONE WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS (this “Amendment”) is entered into as of November 2, 2026, by and among AEON Biopharma, Inc., a Delaware corporation (the “Company”), and each o... |
| 26 Oct 2026 | DEF 14A |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure
Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / OCTOBER 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A |
| 13 Oct 2026 | PRE 14A |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work |
| 21 Aug 2026 | SCHEDULE 13G |
| 21 Aug 2026 |
Form 4: Lynch Timothy P, 10% owner
Bought 1,150,000 shares ($243K) |
| 21 Aug 2026 |
Form 3: Lynch Timothy P, 10% owner
Holds 5,350,000 shares of Class A Common Stock |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Aliso Viejo, Calif., August 3, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic us... |
| 23 Jul 2026 |
8-K: Other Events
As previously reported, on July 15, 2026, AEON Biopharma, Inc. (the “Company”) completed a public offering (the “Offering”), pursuant to an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as r... |
| 21 Jul 2026 | SCHEDULE 13G |
Loading...